ScienceTherapeutic Focus Areas

Type 1 Diabetes

Exploring new potential therapy in new-onset type 1 diabetes

Type 1 diabetes (T1D) is an autoimmune disease in which insulin-producing beta cells in the pancreas are mistakenly destroyed by the body’s immune system. T1D seems to have a genetic component and can be diagnosed early in life but also in adulthood. Its causes are not fully known, and there is currently no cure. People with T1D are dependent on injected or pumped insulin.

More than 10 million suffer from Type 1 diabetes globally. 100,000 new patients/year diagnosed globally in the U.S. alone: 3 million patients, with 30,000 new patients diagnosed annually.

Type 1 diabetes is a chronic disease that requires constant management. People with T1D continuously and carefully balance insulin intake with eating, exercise and other activities. They also measure blood-sugar levels through finger pricks, ideally at least several times a day, or by wearing a continuous glucose monitor.

Even with a strict regimen, people with T1D may still experience dangerously high or low blood-glucose levels that can, in extreme cases, be life threatening.

Studies have shown that AAT may protect beta cell islets, delay the progression of autoimmune diabetes, Inhibit insulitis and beta-cell apoptosis and decrease beta-cell inflammation. Kamada is evaluating the efficacy and safety of plasma-derived, Alpha-1 Antitrypsin (AAT) in the treatment of newly diagnosed Type 1 Diabetes patients.